Evidence map›Paper›PMID 35013990›Full record

ReviewJournal of endocrinological investigation2022

Effects of glycine on metabolic syndrome components: a review.

M Imenshahidi, H Hossenzadeh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  5. Article
  6. Article
  7. Qianyang Yuyin granule modulates glycolysis and inflammatory response to treat hypertensive cardiac remodeling.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Article
  8. Article
  9. Current pharmaceutical design · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Identification of novel hypertension biomarkers using explainable AI and metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

M ImenshahidiDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID http://orcid.org/0000-0002-2441-0421
H HossenzadehDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. hosseinzadehh@mums.ac.ir.ORCID http://orcid.org/0000-0002-3483-851X
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlycine is the simplest and major amino acid in humans. It is mainly generated in the liver and kidney and is used to produce collagen, creatine, glucose and purine. It is also involved in immune function, anti-inflammatory processes and anti-oxidation reactions. Here, we reviewed the current evidence supporting the role of glycine in the development and treatment of metabolic syndrome components.

methodsWe searched Scopus, PubMed and EMBASE databases for papers concerning glycine and metabolic syndrome.

resultsAvailable evidence shows that the amount of glycine synthesized in vivo is insufficient to meet metabolic demands in these species. Plasma glycine levels are lower in subjects with metabolic syndrome than in healthy individuals. Interventions such as lifestyle modification, exercise, weight loss, or drugs that improve manifestations of metabolic syndrome remarkably increase circulating glycine concentrations.

conclusionGlycine supplementation improves various components of metabolic syndrome including diabetes, obesity, hyperlipidemia and hypertension. In the future, the use of glycine may have a significant clinical impact on the treatment of patients with metabolic syndrome.

Indexed as

Metabolic SyndromeExerciseGlycineHumansLife StyleObesityGlycineBlood pressureDiabetesGlycineHyperlipidemiaMetabolic syndromeObesity

Identifiers

PMID35013990
OpenAlexW4205301746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.